Therapeutic Potency of Mono- and Diprenylated Acetophenones: A Case Study of In-Vivo Antimalarial Evaluation

M. H. Yahya, Sodeeq A. Babalola, A. Idris, A. Hamza, Nosakhare Igie, Isaiah Odeyemi, A. Musa, A. Olorukooba
{"title":"Therapeutic Potency of Mono- and Diprenylated Acetophenones: A Case Study of In-Vivo Antimalarial Evaluation","authors":"M. H. Yahya, Sodeeq A. Babalola, A. Idris, A. Hamza, Nosakhare Igie, Isaiah Odeyemi, A. Musa, A. Olorukooba","doi":"10.1055/s-0043-1764210","DOIUrl":null,"url":null,"abstract":"Abstract Malaria remains a febrile infection of public health concern in many countries especially tropical countries in Africa and certain countries in Southern and North America such as Brazil, Costa Rica, Mexico, Dominican Republic, Colombia, and Ecuador. Hence this has made research into this area paramount. Acetophenones are active fragments in many compounds with promising antimalarial activity, such as chalcones. The aim of the present study was to investigate antimalarial activity of 3,5-diprenyl acetophenone ( I ) and 5-diprenyl acetophenone ( II ) in in vivo . In this study, compounds I and II were synthesized using an aromatic substitution reaction. The in-vivo antimalarial potential of compounds I and II was analyzed in Plasmodium berghei -infected mice. Our data showed that compound I (25, 50, and 100 mg/kg) had promising antimalarial activity, with parasitemia inhibited rate being 68.03, 65.16, and 69.75%, respectively. Compound II dose-dependently inhibited parasitemia levels, it demonstrated an infinitesimally higher activity (72.12%) when compared with compound I (69.75%) at 100 mg/kg dose. The two compounds passed the rule of three, Lipinski's rule of five, predicted plausible pharmacokinetic profile (ADME), and apparent safety profile, and demonstrated drug-like fragments. The study provided guidance in exploring novel antimalarial compounds based on the scaffolds of prenylated acetophenones.","PeriodicalId":19767,"journal":{"name":"Pharmaceutical Fronts","volume":"10 1","pages":"e15 - e24"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Fronts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0043-1764210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Malaria remains a febrile infection of public health concern in many countries especially tropical countries in Africa and certain countries in Southern and North America such as Brazil, Costa Rica, Mexico, Dominican Republic, Colombia, and Ecuador. Hence this has made research into this area paramount. Acetophenones are active fragments in many compounds with promising antimalarial activity, such as chalcones. The aim of the present study was to investigate antimalarial activity of 3,5-diprenyl acetophenone ( I ) and 5-diprenyl acetophenone ( II ) in in vivo . In this study, compounds I and II were synthesized using an aromatic substitution reaction. The in-vivo antimalarial potential of compounds I and II was analyzed in Plasmodium berghei -infected mice. Our data showed that compound I (25, 50, and 100 mg/kg) had promising antimalarial activity, with parasitemia inhibited rate being 68.03, 65.16, and 69.75%, respectively. Compound II dose-dependently inhibited parasitemia levels, it demonstrated an infinitesimally higher activity (72.12%) when compared with compound I (69.75%) at 100 mg/kg dose. The two compounds passed the rule of three, Lipinski's rule of five, predicted plausible pharmacokinetic profile (ADME), and apparent safety profile, and demonstrated drug-like fragments. The study provided guidance in exploring novel antimalarial compounds based on the scaffolds of prenylated acetophenones.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
单苯乙酮和双苯乙酮的治疗效能:体内抗疟疾评价的案例研究
在许多国家,疟疾仍然是一种引起公共卫生关注的发热性感染,尤其是在非洲的热带国家以及南美和北美的某些国家,如巴西、哥斯达黎加、墨西哥、多米尼加共和国、哥伦比亚和厄瓜多尔。因此,这使得对这一领域的研究变得至关重要。苯乙酮是许多具有抗疟活性的化合物中的活性片段,如查尔酮。本研究的目的是研究3,5-二烯丙基苯乙酮(I)和5-二烯丙基苯乙酮(II)的体内抗疟活性。本研究采用芳香取代反应合成了化合物I和II。在感染伯氏疟原虫的小鼠体内分析了化合物I和II的体内抗疟潜力。结果表明,化合物1(25、50和100 mg/kg)具有良好的抗疟活性,对寄生虫的抑制率分别为68.03、65.16和69.75%。化合物II具有剂量依赖性,在100 mg/kg剂量下,其抑制寄生虫水平的活性(72.12%)高于化合物I(69.75%)。这两种化合物通过了三法则和利平斯基五法则,预测了合理的药代动力学特征(ADME)和明显的安全性特征,并显示出药物样片段。该研究为以苯乙酮为骨架的新型抗疟药物的开发提供了指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
24
审稿时长
15 weeks
期刊最新文献
Recent Advances in Mitochondrial Pyruvate Carrier Inhibitors Discovery of a Novel Benzimidazole Necroptosis Inhibitor from an In-House Compound Library Research Strategies for Precise Manipulation of Micro/Nanoparticle Drug Delivery Systems Using Microfluidic Technology: A Review Advances in Tumor Targeting Biomimetic Drug Delivery Systems: A Promising Approach for Antitumor Therapy 3D Printing Pharmaceuticals: Current Status and Future Opportunities
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1